Showing results (2251-2260 of 2,317) with videos related to
Sort By:
Pageof 232
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal JunctionJin Li, Shukui Qin, Jianming Xu, et al.The Lancet. Oncology|November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.The Lancet. Gastroenterology & Hepatology|May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialShukui Qin, Qiu Li, Shanzhi Gu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2023
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 TrialJianchun Duan, Lin Wu, Kunyu Yang, et al.Journal of Cancer Research and Clinical Oncology|June 14, 2023
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS studyQing Zhou, He-Long Zhang, Li-Yan Jiang, et al.Molecular Cancer|January 4, 2022
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trialTao Jiang, Jianhua Chen, Xingxiang Xu, et al.Targeted Oncology|January 12, 2022
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in ChinaHai-Yan Tu, Jifeng Feng, Meiqi Shi, et al.Lipids in Health and Disease|December 28, 2024
Familial hypercholesterolemia in Chinese children and adolescents: a multicenter studyMeng-Na Huang, Chen-Cen Wang, Ming-Sheng Ma, et al.The Oncologist|June 9, 2021
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)Yihebali Chi, Yongqian Shu, Yi Ba, et al.Lancet (London, England)|July 27, 2023
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyShukui Qin, Stephen L Chan, Shanzhi Gu, et al.Pageof 232